Sanofi's Lemtrada wins Brazilian OK; Novartis poster campaign highlights meningitis; Selfies help raise millions for cancer charities;

> ViiV Healthcare has announced the next round of its Positive Action Southern Initiative, which works with community organizations in Alabama, Georgia, Louisiana and Mississippi to support linkages to HIV/AIDS care and treatment among at-risk populations. Release

> Sanofi's ($SNY) Genzyme has won approval from Brazil's national health surveillance agency for multiple sclerosis drug Lemtrada. Release

> Eli Lilly ($LLY) has launched an online training tool to help patient advocates understand health technology assessment. More

> Novartis ($NVS) has launched a poster campaign in Germany to raise public awareness about meningococcal bacteria and vaccines. More

> Astellas has won marketing approval in Japan for its prostate cancer treatment Xtandi. Release

> Novartis ($NVS) is launching a Lucentis prefilled syringe in Europe, which it says will reduce the risk of adverse events from nonsterile conditions. Release

> England has added Celgene's ($CELG) Abraxane, Roche's ($RHHBY) Avastin and Exelixis's Cometriq to its Cancer Drugs Fund, which offers access to meds not routinely funded by its National Health Service. More

> Experts say health apps are the "key to patient-centered healthcare." More

> Axxess Pharma has launched two websites to market its muscle supplements; the company believes they will help generate an additional $1.5 million in gross monthly sales within 45 days. Release

And Finally... The hashtag #nomakeupselfie has helped raise more than £8 million ($13.2 million) for cancer charities, with women posting photos highlighting the risks of cancer and then donating to a range of charities. More